# US 2012/0252877 A1 · Methods and compositions for treatment of tuberous sclerosis complex

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252877 A1
- Document ID: US20120252877A1
- Status: Published application
- Kind: A1
- Application number: 13/390,107
- Filed: 2010-08-16
- Published: 2012-10-04
- Earliest claimed: 2009-08-14
- Assignees: Theramind Research, LLC
- Inventors: Loon-Tzian Lo
- Web page: https://patentgrep.com/patent/US20120252877A1

## CPC

- C12N 15/86: Viral vectors
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 14/47: from mammals
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to a method of treating Tuberous Sclerosis Complex (TSC). The present disclosure further provides an isolated polynucleotide molecule comprising, a polynucleotide comprising an AAV9 vector; a polynucleotide encoding a TSC1 or a TSC2, or variant thereof; and a promoter. The present disclosure further provides a pharmaceutical composition comprising an isolated polynucleotide molecule.

## Claims

### Claim 1

A method of treating Tuberous Sclerosis Complex (TSC), the method comprising
administering to a subject in need thereof a therapeutically effective amount of a composition comprising an adeno-associated virus (AAV) vector, the AAV vector comprising at least one polynucleotide encoding a TSC1 or a TSC2, or variant thereof;
wherein TSC1 or TSC2 is expressed in a plurality of cells of the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the AAV vector comprises a polynucleotide encoding a TSC1, or variant thereof, having a nucleic acid sequence selected from the group consisting of:
SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22;
a nucleic acid sequence having at least about 90% identity to SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22 and encoding a polypeptide having hamartin activity;
a nucleic acid sequence encoding a polypeptide of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, or SEQ ID NO: 21; and
a nucleic acid sequence encoding a polypeptide having at least about 90% identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, or SEQ ID NO: 21 and having hamartin activity.

### Claim 3 (depends on 1)

The method of claim 1, wherein the AAV vector comprises a polynucleotide encoding a TSC2, or variant thereof, having a nucleic acid sequence selected from the group consisting of:
SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, or SEQ ID NO: 30;
a nucleic acid sequence having at least about 90% identity to SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, or SEQ ID NO: 30 and encoding a polypeptide having tuberin activity;
a nucleic acid sequence encoding a polypeptide of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, or SEQ ID NO: 29; and
a nucleic acid sequence encoding a polypeptide having at least about 90% identity to SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, or SEQ ID NO: 29 and having tuberin activity.

### Claim 4 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein the at least one polynucleotide is operably linked to a heterologous promoter.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any of claims 1-4, wherein the heterologous promoter is selected from the group consisting of: a glial fibrillary acidic protein (GFAP) promoter, a synapsin-1 (SYN) promoter, a Ca2+/calmodulin-dependent protein kinase II (CAMKII) promoter, a myelin basic protein (MBP) promoter, a nectin promoter, a myosin light polypeptide 2 (Myl-2) promoter, a SM22α gene promoter, a human cytomegalovirus immediate-early gene (CMV) promoter, and a human ubiquitin 6 (U6) promoter.

### Claim 6 (depends on 4)

The method of claim 4, wherein the heterologous promoter is a glial fibrillary acidic protein (GFAP) promoter.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any of claims 1-6, wherein the administering comprises intravenous administration.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any of claims 1-7, wherein the subject in need of treatment displays at least one symptom selected from the group consisting of: brain tubers, brain tumors, subependymal nodules, subependymal giant cell astrocytomas, vascular stromas, peripheral nervous system tumors, retinal hamartomas, seizures, mental retardation, learning disabilities, behavior problems, autism, autism spectrum disorders, attention deficit hyperactivity disorder, and sleep disturbances.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any of claims 1-8, wherein the subject in need of treatment displays at least one symptom selected from the group consisting of: renal lesions caused by angiomyolipomas, simple cysts, polycystic kidney disease, renal-cell carcinoma, renal lymphangiomyomatosis, cardiac lesion caused by cardiac rhabdomyomas, dermatological lesions caused by hyperpigmented maculars, angiofibromas, fibrous plaques, papules, Shagreen patches, gingival fibromas, and pulmonary lesions caused by lymphangiomyomatosis.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any of claims 1-9, wherein the AAV vector is an AAV9 vector.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any of claims 1-10, further comprising measuring one or more of:
(i) the expression of TSC1 or TSC2, wherein at least one of the polynucleotides for TSC1 or TSC2 is comprised by the AAV vector;
(ii) the activity level of a polypeptide encoded in the AAV vector; or
(iii) the level of mTOR signaling in cells comprised by the subject.

### Claim 12 (depends on 11)

The method of claim 11, further comprising comparing the expression of TSC1 or TSC2 in the subject being treated for TSC to the expression of TSC1 or TSC2 in a subject who is not in need of treatment for TSC.

### Claim 13 (depends on 11)

The method of claim 11, further comprising comparing the activity level of a polypeptide encoded in the AAV vector or the activity level of mTOR signaling in cells comprised by the subject being treated for TSC to the activity level of a polypeptide encoded in the AAV vector or the activity level of mTOR signaling in a subject who is not in need of treatment for TSC.

### Claim 14

An isolated polynucleotide molecule comprising:
(i) a polynucleotide comprising an AAV9 vector;
(ii) a polynucleotide encoding a TSC1 or a TSC2, or variant thereof; and
(iii) a promoter;
wherein the promoter is operably linked to the polynucleotide encoding a TSC1 or a TSC2, or variant thereof.

### Claim 15 (depends on 14)

The isolated polynucleotide molecule of claim 14, wherein the polynucleotide encoding TSC1 or TSC2, or variant thereof, is selected from the group consisting of:
SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22;
a nucleic acid sequence having at least about 90% identity to SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 22 and encoding a polypeptide having hamartin activity;
a nucleic acid sequence encoding a polypeptide of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, or SEQ ID NO: 21;
a nucleic acid sequence encoding a polypeptide having at least about 90% identity to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, or SEQ ID NO: 21 and encoding a polypeptide having hamartin activity;
SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, or SEQ ID NO: 30;
a nucleic acid sequence having at least about 90% identity to SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, or SEQ ID NO: 30 and encoding a polypeptide having tuberin activity;
a nucleic acid sequence encoding a polypeptide of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, or SEQ ID NO: 29; and
a nucleic acid sequence encoding a polypeptide having at least about 90% identity to SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, or SEQ ID NO: 29 and encoding a polypeptide having tuberin activity.

### Claim 16 (depends on 14, 15)

The isolated polynucleotide molecule of any of claims 14-15, wherein the promoter is a human cytomegalovirus promoter.

### Claim 17 (depends on 16)

The isolated polynucleotide molecule of claim 16, wherein the human cytomegalovirus promoter comprises a nucleic acid sequence of SEQ ID NO: 9, or 90% identity thereto and having cytomegalovirus promoter activity.

### Claim 18 (depends on 14)

The isolated polynucleotide molecule of claim 14, wherein the sequence of the isolated polynucleotide comprises SEQ ID NO: 12.

### Claim 19 (depends on 14, 15, 16, 17, 18)

A pharmaceutical composition comprising the isolated polynucleotide molecule of any of claims 14-18 and a pharmaceutically acceptable carrier or excipient.

### Claim 20 (depends on 14, 15, 16, 17, 18)

A virion comprising the isolated polynucleotide of any of claims 14-18, wherein the virion is capable of delivering cargo to human cells.

### Claim 21 (depends on 19)

The virion of claim 19, wherein the virion comprises AAV9 capsid or AAV9 capsid comprising mutations not found in naturally-occurring isolates of AAV9.

### Claim 22 (depends on 14, 15, 16, 17, 18)

A cell comprising the isolated polynucleotide of any of claims 14-18.

### Claim 23 (depends on 14, 15, 16, 17, 18)

Use of an isolated polynucleotide molecule for the treatment of Tuberous Sclerosis Complex (TSC), the isolated polynucleotide molecule comprising:
(a) the isolated polynucleotide molecule of any one of claims 14-18; or
(b) (i) a polynucleotide comprising an AAV9 vector, (ii) a polynucleotide encoding a TSC1 or a TSC2, or variant thereof, and (iii) a promoter, wherein the promoter is operably linked to the polynucleotide encoding a TSC1 or a TSC2, or variant thereof.

### Claim 24 (depends on 14, 15, 16, 17, 18)

The use of isolated polynucleotide molecule in the manufacture of a medicament for the treatment of Tuberous Sclerosis Complex (TSC), the isolated polynucleotide molecule comprising:
(a) the isolated polynucleotide molecule of any one of claims 14-18; or
(b) (i) a polynucleotide comprising an AAV9 vector, (ii) a polynucleotide encoding a TSC1 or a TSC2, or variant thereof, and (iii) a promoter, wherein the promoter is operably linked to the polynucleotide encoding a TSC1 or a TSC2, or variant thereof.
